|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Revenue, net | |||||
| Product revenue, net | |||||
| License | |||||
| Total revenue, net | |||||
| Operating expenses | |||||
| Cost of product revenue | |||||
| Research and development | |||||
| Sales and marketing | |||||
| General and administrative | |||||
| Impairment loss on indefinite-lived intangible assets | |||||
| Total operating expenses | |||||
| Loss from operations | |||||
| Changes in fair value of freestanding and hybrid financial instruments designated at Fair Value Option | |||||
| Gain (loss) on extinguishment of debt | |||||
| Interest income (expense) | |||||
| Other income (expense) | |||||
| Loss before income tax expense | |||||
| Income tax expense | |||||
| Net loss | |||||
| Net loss attributable to noncontrolling interest | |||||
| Deemed dividend to preferred stockholders | |||||
| Net loss attributable to common stockholders | |||||
| Net loss per share, basic | |||||
| Net loss per share, diluted | |||||
| Weighted-average common stock outstanding, basic | |||||
| Weighted-average common stock outstanding, diluted | |||||
Loading...